drugset / Trial / NCT01289938
Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine
RandomizedSingle-groupOpen-labelBasic science
Summary
Pharmacokinetic of Metoclopramide (MCP) in correlation to polymorphisms of CYP2D6 and Dopamine-D2-Receptor. Pharmacokinetic of Diphenhydramine (DPH) in correlation to polymorphisms of CYP2D6
Timeline
- Start
- 2009-07
- Primary completion
- 2015-06
- Completion
- 2015-06
Outcome
Outcome not reported
Stopped (Enrollment): “To unsuccessful recruitment of rare UM-genotype. All other planned genotype groups are completed (EM, IM and PM).”
Publications
- Background Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta. 2007 Mar;1770(3):489-94. doi: 10.1016/j.bbagen.2006.09.019. Epub 2006 Oct 4.
- Background Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007 Nov 20;25(33):5187-93. doi: 10.1200/JCO.2007.12.2705.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Diphenhydramine | Small molecule | 50 mg | Oral |
| Comparator | Metoclopramide | Small molecule | 10 mg | Intravenous |
Indications
No indication recorded.